References
1. Farmakis D, Stafylas P, Giamouzis G, Maniadakis N, Parissis J. The
medical and socioeconomic burden of heart failure: A comparative
delineation with cancer. Int J Cardiol. 2016; 203: 279–81.
https://doi.org/10.1016/j.ijcard.2015.10.172
2. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong
S, et al. Heart Failure Stimulates Tumor Growth by Circulating Factors.
Circulation. 2018; 138(7):678-91.
https://doi.org/10.1161/CIRCULATIONAHA.117.030816
3. Michel L, Schadendorf D, Rassaf T. Oncocardiology: new challenges,
new opportunities. Herz. 2020; 45(7): 619–25.
https://doi.org/10.1007/s00059-020-04951-x
4. Abdel-Rahman O. Risk of cardiac death among cancer survivors in the
United States: a SEER database analysis. Expert Rev Anticancer Ther.
2017;17(9): 873–78. https://doi.org/10.1080/14737140.2017.1344099
5. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et
al. Cardiovascular Health of Patients With Cancer and Cancer Survivors:
A Roadmap to the Next Level. J Am Coll Cardiol. 2015; 65(25): 2739–46.
https://doi.org/10.1016/j.jacc.2015.04.059
6. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van
der Meer P, et al. Cardio-Oncology Services: rationale, organization,
and implementation. Eur Heart J 2019; 40(22): 1756–63.
https://doi.org/10.1093/eurheartj/ehy453
7. Writing Committee Members; ACC/AHA Joint Committee Members. 2022
AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail.
2022; 28(5): e1–e167. https://doi.org/10.1016/j.cardfail.2022.02.010
8. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et
al. Long-term cardiac tolerability of trastuzumab in metastatic breast
cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;
24(25): 4107–15. https://doi.org/10.1200/JCO.2005.04.9551
9. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate
T, et al. Risk of heart failure in breast cancer patients after
anthracycline and trastuzumab treatment: a retrospective cohort study. J
Natl Cancer Inst. 2012; 104(17): 1293–305.
https://doi.org/10.1093/jnci/djs317
10. Yoodee J, Sookprasert A, Sanguanboonyaphong P, Chanthawong S,
Seateaw M, Subongkot S. An Exploration of Heart Failure Risk in Breast
Cancer Patients Receiving Anthracyclines with or without Trastuzumab in
Thailand: A Retrospective Study. Clin Pract. 2021; 11(3): 484–93.
https://doi.org/10.3390/clinpract11030064
11. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi
G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and
response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55(3):
213–20. https://doi.org/10.1016/j.jacc.2009.03.095
12. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf.
2008; 31(6): 459–67. https://doi.org/10.2165/00002018-200831060-00002
13. Chang WT, Chen PW, Lin HW, Lin SH, Li YH. Risks of
trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan.
ESC Heart Fail. 2021; 8(6): 5149–58. https://doi.org/10.1002/ehf2.13591
14. Alhussein MM, Mokbel A, Cosman T, Aghel N, Yang EH, Mukherjee SD, et
al. Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A
SystematicReview and Meta-analysis. CJC Open. 2021; 3(11): 1372–82.
https://doi.org/10.1016/j.cjco.2021.06.019
15. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling
LM, et al. Myocarditis in Patients Treated With Immune Checkpoint
Inhibitors. J Am Coll Cardiol. 2018; 71(16): 1755–64.
https://doi.org/10.1016/j.jacc.2018.02.037
16. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia
F, et al. Early detection of anthracycline cardiotoxicity and
improvement with heart failure therapy. Circulation. 2015; 131(22):
1981–88. https://doi.org/10.1161/CIRCULATIONAHA.114.013777
17. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al.
Protective effects of spironolactone against anthracycline-induced
cardiomyopathy. Eur J Heart Fail. 2015; 17(1): 81–9.
https://doi.org/10.1002/ejhf.196
18. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt
TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced
left ventricular systolic dysfunction in patients with malignant
hemopathies: the OVERCOME trial (preventiOn of left Ventricular
dysfunction with Enalapril and caRvedilol in patients submitted to
intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am
Coll Cardiol. 2013; 61(23): 2355–62.
https://doi.org/10.1016/j.jacc.2013.02.072
19. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M,
et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in
high-risk patients by angiotensin-converting enzyme inhibition.
Circulation. 2006; 114(23): 2474–81.
https://doi.org/10.1161/CIRCULATIONAHA.106.635144
20. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L,
McCaskill-Stevens W, et al. Randomized Trial of Lisinopril Versus
Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast
Cancer. J Am Coll Cardiol. 2019; 73(22): 2859–68.
https://doi.org/10.1016/j.jacc.2019.03.495
21. Brown LJ, Meredith T, Yu J, Patel A, Neal B, Arnott C, et al. Heart
Failure Therapies for the Prevention of HER2-Monoclonal
Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis
of Randomized Trials. Cancers (Basel). 2021; 13(21): 5527.
https://doi.org/10.3390/cancers13215527
22. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores
Cruz F, Gonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for
Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am
Coll Cardiol. 2018; 71(20): 2281–90.
https://doi.org/10.1016/j.jacc.2018.02.049
23. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M,
et al. Anthracycline-induced cardiotoxicity: A multicenter randomised
trial comparing two strategies for guiding prevention with enalapril:
The International CardioOncology Society-one trial. Eur J Cancer. 2018;
94: 126–37. https://doi.org/10.1016/j.ejca.2018.02.005
24. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et
al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology
Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention
of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017; 35(8):
870–7. https://doi.org/10.1200/JCO.2016.68.7830
25. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV.
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
JACC Heart Fail. 2020; 8(10): 800–10.
https://doi.org/10.1016/j.jchf.2020.06.020
26. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR,
et al. Angiotensin-neprilysin inhibition versus enalapril in heart
failure. N Engl J Med. 2014; 371(11): 993–1004.
https://doi.org/10.1056/NEJMoa1409077
27. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K,
et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart
Failure. N Engl J Med. 2019; 380(6): 539–48.
https://doi.org/10.1056/NEJMoa1812851
28. DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty
H, et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute
Decompensated Heart Failure: Secondary Analysis of the Open-label
Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020; 5(2): 202–7.
https://doi.org/10.1001/jamacardio.2019.4665
29. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular
dilatation and the risk of congestive heart failure in people without
myocardial infarction. N Engl J Med. 1997; 336(19): 1350–5.
https://doi.org/10.1056/NEJM199705083361903
30. Wong M, Johnson G, Shabetai R, Hughes V, Bhat G, Lopez B, et al.
Echocardiographic variables as prognostic indicators and therapeutic
monitors in chronic congestive heart failure. Veterans Affairs
cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies
Group. Circulation. 1997; 87 (6 Suppl):VI65-70.
31. Correale M, Mallardi A, Tricarico L, Mazzeo P, Ferraretti A, Diella
C, et al. Remodelling is inversely proportional to left ventricular
dimensions in a real-life population of patients with chronic heart
failure after therapy with sacubitril/valsartan. Acta Cardiol. 2021;
77(5): 416–21. https://doi.org/10.1080/00015385.2021.1950371
32. Duraes AR, de Souza Lima Bitar Y, Neto MG, Mesquita ET, Chan JS, Tse
G, et al. Effectiveness of sacubitril-valsartan in patients with cancer
therapy-related cardiac dysfunction (CTRCD): a systematic review of
clinical and preclinical studies. Minerva Med. 2022; 113(3): 551–7.
https://doi.org/10.23736/S0026-4806.22.08029-6
33. Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K, et al. LCZ696 improves
cardiac function via alleviating Drp1-mediated mitochondrial dysfunction
in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell
Cardiol. 2017; 108:138-48. https://doi.org/10.1016/j.yjmcc.2017.06.003
34. Dindaş F, Güngör H, Ekici M, Akokay P, Erhan F, Doğduş M, et al.
Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan
attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice
model by interfering with oxidative stress, inflammation, and Caspase 3
apoptotic pathway. Anatol J Cardiol. 2021; 25(11): 821–8.
https://doi.org/10.5152/AnatolJCardiol.2021.356
35. Boutagy NE, Feher A, Pfau D, Liu Z, Guerrera NM, Freeburg LA, et al.
Dual Angiotensin Receptor-Neprilysin Inhibition With
Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental
Doxorubicin-Induced Cardiotoxicity. JACC CardioOncol. 2020; 2(5):
774–87. https://doi.org/10.1016/j.jaccao.2020.09.007
36. Kim BS, Park IH, Lee AH, Kim HJ, Lim YH, Shin JH.
Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model
of doxorubicin-induced cardiotoxicity. Arch Toxicol. 2022; 96(4):
1065–74. https://doi.org/10.1007/s00204-022-03241-1
37. Sheppard CE, Anwar M. The use of sacubitril/valsartan in
anthracycline-induced cardiomyopathy: A mini case series. J Oncol Pharm
Pract. 2019; 25(5): 1231–4. https://doi.org/10.1177/1078155218783238
38. Canale ML, Coviello K, Solarino G, Del Meglio J, Simonetti F,
Venturini E, et al. Case Series: Recovery of Chemotherapy-Related Acute
Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable
Cardioverter Defibrillator: A Novel Winning Combination in
Cardio-Oncology. Front Cardiovasc Med. 2022; 9:801143.
https://doi.org/10.3389/fcvm.2022.801143
39. Frey MK, Arfsten H, Pavo N, Han E, Kastl S, Hülsmann M, et al.
Sacubitril/valsartan is well tolerated in patients with longstanding
heart failure and history of cancer and improves ventricular function:
real-world data. Cardiooncology. 2021; 7(1): 35.
https://doi.org/10.1186/s40959-021-00121-y
40. Martín-Garcia A, López-Fernández T, Mitroi C, Chaparro-Muñoz M,
Moliner P, Martin-Garcia AC, et al. Effectiveness of
sacubitril-valsartan in cancer patients with heart failure. ESC Heart
Fail. 2020; 7(2), 763–7. https://doi.org/10.1002/ehf2.12627
41. De Vecchis R, Paccone A. A case series about the favorable effects
of sacubitril/valsartan on anthracycline cardiomyopathy. SAGE Open Med
Case Rep. 2020; 8:2050313X20952189.
https://doi.org/10.1177/2050313X20952189
42. Martín-García A, Díaz-Peláez E, Martín-García AC, Sánchez-González
J, Ibáñez B, Sánchez PL. Myocardial function and structure improvement
with sacubitril/valsartan in cancer therapy-induced cardiomyopathy. Rev
Esp Cardiol (Engl Ed). 2020; 73(3): 268–269.
https://doi.org/10.1016/j.rec.2019.07.006
43. Gregorietti V, Fernandez TL, Costa D, Chahla EO, Daniele AJ. Use of
Sacubitril/valsartan in patients with cardio toxicity and heart failure
due to chemotherapy. Cardiooncology. 2020; 6(1): 24.
https://doi.org/10.1186/s40959-020-00078-4
44. Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric
NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk
factors, pharmacologic prevention, and cardiotoxicity of other
HER2-directed therapies. Breast Cancer Res Treat. 2021; 188(1):21-36.
https://doi.org/10.1007/s10549-021-06280-x
45. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al.
Prospective evaluation of the cardiac safety of HER2-targeted therapies
in patients with HER2-positive breast cancer and compromised heart
function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019; 175(3):
595–603. https://doi.org/10.1007/s10549-019-05191-2
46. Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen
RA. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity
Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older
Adults With Breast Cancer. Am J Clin Oncol. 2018; 41(9):909–18.
https://doi.org/10.1097/COC.0000000000000389
47. Xi Q, Chen Z, Li T, Wang L. Time to switch angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan
in patients with cancer therapy-related cardiac dysfunction. J Int Med
Res. 2022; 50(1):3000605211067909.
https://doi.org/10.1177/03000605211067909
48. Lupi A, Ariotti S, De Pace D, Ferrari I, Bertuol S, Monti L, et al.
Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing
Hairy Cell Leukaemia: Case Report. Clin Med Insights Cardiol. 2021;
15:11795468211010706. https://doi.org/10.1177/11795468211010706
49. Wu SJ, Liu XH, Wu W, Qian M, Li L, Zhang L, et al. [Tocilizumab
therapy for immune checkpoint inhibitor associated myocarditis: a case
report]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022; 50(4):397-400.
Chinese. https://doi.org/10.3760/cma.j.cn112148-20210511-00412
50. Mecinaj A, Gulati G, Heck SL, Holte E, Fagerland MW, Larsen AI, et
al. Rationale and design of the PRevention of cArdiac Dysfunction during
Adjuvant breast cancer therapy (PRADA II) trial: a randomized,
placebo-controlled, multicenter trial. Cardiooncology. 2021; 7(1): 33.
https://doi.org/10.1186/s40959-021-00115-w